Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma

T-cell redirection therapy using chimeric antigen receptor (CAR) T cells and bispecific antibodies (BiAbs) has shown promising efficacy in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM), leading to the approval of 2 CAR T-cell products and numerous BiAb trials. Data on...

Descripción completa

Detalles Bibliográficos
Autores principales: Mouhieddine, Tarek H., Van Oekelen, Oliver, Melnekoff, David T., Li, Jeanne, Ghodke-Puranik, Yogita, Lancman, Guido, Thibaud, Santiago, Pan, Darren, Rajeeve, Sridevi, Agte, Sarita, Aleman, Adolfo, Sanchez, Larysa, Richard, Shambavi, Rossi, Adriana, Richter, Joshua, Cho, Hearn Jay, Rodriguez, Cesar, Lagana, Alessandro, Moshier, Erin, Chari, Ajai, Jagannath, Sundar, Parekh, Samir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033902/
https://www.ncbi.nlm.nih.gov/pubmed/36018226
http://dx.doi.org/10.1182/bloodadvances.2022007923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033902/
https://www.ncbi.nlm.nih.gov/pubmed/36018226
http://dx.doi.org/10.1182/bloodadvances.2022007923

Ejemplares similares